Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+8.49%+20.55%+69.74%+109.30% 62.92B
+1.25%+2.44%+32.55%+72.63% 54.32B
-1.09%+32.96%+19.95%+499.45% 28.73B
+2.72%+3.41%-15.88%-4.90% 22.91B
+10.83%+18.38%+52.76%+4.58% 21.65B
+6.50%+7.56%+38.20%-21.33% 17.76B
-3.88%+16.98%+199.30%+354.30% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
+3.58%+1.96%+44.61%+167.01% 13.12B
Average +3.46%+9.40%+52.91%+206.99% 28.15B
Weighted average by Cap. +4.19%+11.45%+49.71%+171.15%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-